Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
AIDS Care ; 31(6): 681-686, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30350713

RESUMEN

Sexual life is an important dimension of quality of life, which may be affected by the fear of transmission in people living with HIV/AIDS (PLWHA), despite the fact that antiretroviral therapy prevents person-to-person transmission. We, therefore, aimed to explore the sexual life satisfaction of PLWHA and its correlation with their fear of HIV transmission and self-esteem. Consecutive adult PLWHA from seven HIV care facilities in the Rhone-Alpes region, France, were asked to complete a self-administered, anonymous questionnaire concerning sociological and medical data, satisfaction with sexual life (18 questions), and self-esteem (Rosenberg score). Overall, 690 PLWHA answered the questionnaire (mean age 49.2 ± 11 years); 74.9% were men, of which 75.1% had sex with men. Overall, 68.0% of respondents feared transmitting HIV (a lot/a bit). A lower satisfaction with sexual life was significantly associated with being female, not having a stable sexual partner, being unemployed, having a low income, experiencing a fear of HIV transmission, having lower self-esteem, and not reporting an excellent/very good health status. These results strongly suggest that the information concerning the antiretroviral-induced suppression of infectivity should be widely diffused, as this may enhance the quality of sexual life in PLWHA.


Asunto(s)
Miedo , Infecciones por VIH/psicología , Satisfacción Personal , Calidad de Vida/psicología , Autoimagen , Adolescente , Adulto , Antirretrovirales/uso terapéutico , Femenino , Francia , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/transmisión , Humanos , Masculino , Persona de Mediana Edad , Conducta Sexual/estadística & datos numéricos , Parejas Sexuales , Encuestas y Cuestionarios , Adulto Joven
2.
Diabet Med ; 29(1): 56-61, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21838765

RESUMEN

AIMS: To assess the outcome of patients with diabetes with suspicion of osteomyelitis of the foot who had undergone a percutaneous bone biopsy that yielded negative microbiological results, with focus on the occurrence of osteomyelitis at the biopsied site. METHODS: Medical charts of adult patients with diabetes with a negative percutaneous bone biopsy were reviewed. Patients' outcome was evaluated at least 2 years after the initial bone biopsy according to wound healing, the results of a new bone biopsy and bone imaging evaluation when applicable. RESULTS: From January 2001 to January 2008, 41 patients with diabetes (30 men/11 women; mean age 58.1 ± 9.6 years; mean diabetes duration 15.8 ± 6.7 years) met study criteria. Osteomyelitis was suspected based on combined clinical and imaging diagnostic criteria. On follow-up at a mean duration of 41.2 ± 22.5 months post-bone biopsy, 16 patients had complete wound healing (39.0%). Of the 25 other patients, 15 had a new bone biopsy performed, six of which yielded positive microbiological results, and among the 10 patients who neither healed nor underwent bone biopsy, comparative radiography of the foot showed a stable aspect of the biopsied site in six of them, for whom the data were available. Finally, osteomyelitis of the foot at the site where the initial bone biopsy had been performed was confirmed during follow-up in six patients (14.6%) and was suspected in four additional patients (9.7%). CONCLUSIONS: The results of the present study suggest that, of patients with diabetes with the suspicion of osteomylelitis and a negative percutaneous bone biopsy, only one out of four will develop osteomyelitis within 2 years of the biopsy.


Asunto(s)
Biopsia , Pie Diabético/patología , Huesos del Pie/patología , Osteomielitis/patología , Biopsia/métodos , Pie Diabético/diagnóstico por imagen , Pie Diabético/microbiología , Femenino , Huesos del Pie/diagnóstico por imagen , Huesos del Pie/microbiología , Humanos , Masculino , Persona de Mediana Edad , Osteomielitis/diagnóstico por imagen , Osteomielitis/microbiología , Radiografía , Estudios Retrospectivos , Resultado del Tratamiento , Cicatrización de Heridas
3.
Infect Dis Now ; 51(4): 340-345, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33075403

RESUMEN

INTRODUCTION: Notwithstanding high prevalence of presumably bacterial infections in elderly persons (EP) in palliative care (PC), there exists no recommendation on the role of antibiotic therapy (ABP) in this type of situation. OBJECTIVE: To describe the determinants of antibiotic prescription by general practitioners (GP) and by doctors practicing in institutions (DPI) for patients>75 years, in end-of-life situations in PC. METHOD: Descriptive investigation by anonymous self-administered questionnaire disseminated in France by e-mail. RESULTS: A total of 301 questionnaires analyzed: 113 GP, 188 DPIs. The latter were mainly geriatricians (69, 36.6%) and infectologists/internists (41, 21.8%). Sixty-three (55,75%) GPs and 144 (78.7%) DPIs stated that they had prescribed antibiotics. Practice in "EHPAD" retirement homes or intensive care was often associated with non-prescription of antibiotics. Age, PC training and number of patients monitored bore no influence. Family involvement in decision-making was more frequent for GPs than for DPIs. The main purpose of antibiotic therapy was to relieve different symptoms (fever, respiratory congestion, functional urinary signs). Most of the doctors (81%) had previously encountered complications (allergy, adverse effect), which represented the main causes of treatment discontinuation. CONCLUSION: Antibiotic use in end-of-life EPs in PC seems frequent. In accordance with the principle of beneficence, its goal of often symptom-related; that said, in the absence of scientific data, antibiotic prescription in end-of-life situations should be individualized in view of observing the other ethical caregiving principles (beneficence, non-maleficence, justice, patient autonomy) and re-evaluated daily.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Prescripciones de Medicamentos/estadística & datos numéricos , Cuidados Paliativos/métodos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Cuidado Terminal/métodos , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Fiebre/tratamiento farmacológico , Francia/epidemiología , Médicos Generales , Humanos , Masculino , Persona de Mediana Edad , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Encuestas y Cuestionarios
4.
Med Mal Infect ; 38(12): 671-3, 2008 Dec.
Artículo en Francés | MEDLINE | ID: mdl-18950972

RESUMEN

The authors report an unusual case of prosthetic vascular graft infection due to Salmonellatyphimurium. The initial treatment combined antibiotherapy and surgical replacement of the arteriovenous graft. The infection relapsed within 6 weeks and was successfully treated with antibiotics only. Five cases of vascular graft infection due to Salmonella have been reported so far, but only one occurred in a previously healthy man and was not related to local infection, but to bacteremic seeding. Specific features of vascular graft infection and importance of prevention are discussed.


Asunto(s)
Antibacterianos/uso terapéutico , Prótesis Vascular/efectos adversos , Remoción de Dispositivos , Infecciones Relacionadas con Prótesis/microbiología , Infecciones por Salmonella/etiología , Salmonella typhimurium/aislamiento & purificación , Anciano , Amicacina/administración & dosificación , Amicacina/uso terapéutico , Aorta Abdominal/cirugía , Aneurisma de la Aorta Abdominal/cirugía , Prótesis Vascular/microbiología , Cefotaxima/administración & dosificación , Cefotaxima/uso terapéutico , Ceftriaxona/administración & dosificación , Ceftriaxona/uso terapéutico , Terapia Combinada , Quimioterapia Combinada , Arteria Femoral/cirugía , Humanos , Laparotomía , Masculino , Ofloxacino/administración & dosificación , Ofloxacino/uso terapéutico , Oxacilina/administración & dosificación , Oxacilina/uso terapéutico , Arteria Poplítea/cirugía , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Infecciones Relacionadas con Prótesis/cirugía , Recurrencia , Infecciones por Salmonella/tratamiento farmacológico , Infecciones por Salmonella/microbiología , Infecciones por Salmonella/cirugía , Choque Séptico/etiología
5.
Med Mal Infect ; 38(12): 667-70, 2008 Dec.
Artículo en Francés | MEDLINE | ID: mdl-18951744

RESUMEN

A case of Salmonella paratyphi A infection was diagnosed late in a patient treated for febrile pneumonia after his returning from India. This case was remarkable in two aspects: first, it illustrated the reemergence of S.paratyphi A infections in people having traveled to India, with increasing fluoroquinolone resistance, and second the difficulty of diagnosing this disease, since the patient was initially treated for pneumonia and flu-like syndrome. Salmonella typhi or paratyphi infections should be evoked in case of persistent fever in patients having traveled to endemic areas, even if digestive signs are absent. Furthermore, choosing an empiric antibiotic treatment with fluoroquinolones could lead to treatment failure if the patient traveled in a country where fluoroquinolone resistance is high, as in Asia and especially in India.


Asunto(s)
Fiebre Paratifoidea/diagnóstico , Neumonía Bacteriana/diagnóstico , Salmonella paratyphi A/aislamiento & purificación , Adulto , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Bacteriemia/diagnóstico , Bacteriemia/tratamiento farmacológico , Bacteriemia/microbiología , Bangladesh , Ceftriaxona/uso terapéutico , Farmacorresistencia Bacteriana Múltiple , Enfermedades Endémicas , Fluoroquinolonas/farmacología , Humanos , India , Cetólidos/uso terapéutico , Masculino , Fiebre Paratifoidea/tratamiento farmacológico , Fiebre Paratifoidea/microbiología , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/microbiología , Salmonella paratyphi A/efectos de los fármacos , Viaje
6.
J Chemother ; 19(6): 688-93, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18230552

RESUMEN

The records of 84 patients with bone infections treated with high-dose levofloxacin (i.e. 0.75-1g daily) for more than 4 weeks were reviewed. Patients were given either 500 mg b.i.d. throughout the treatment period [Group 1 (n=41)], 500 mg b.i.d. for 3 weeks and then 750 mg q.d. [Group 2 (n=21)] or 750 mg q.d. for the whole treatment period [Group 3 (n=22)]. All patients had combined therapy, including levofloxacin-rifampin in 62 cases (73.8%), for an average duration of 13.7 weeks. Muscular pain and/or tendonitis were reported in 19 patients (22.6%) which affected more patients in Groups 1 and 2 than in Group 3 (14/41 and 5/21 vs. 0/22; p=0.01 and 0.001, respectively). A dosage of 750 mg q.d. may be warranted for prolonged high-dose levofloxacin treatment in patients with bone infections rather than 500 mg b.i.d. for the entire duration of treatment, or for the first 3 weeks.


Asunto(s)
Antibacterianos/administración & dosificación , Levofloxacino , Ofloxacino/administración & dosificación , Osteomielitis/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Evaluación de Medicamentos , Humanos , Persona de Mediana Edad , Músculos/efectos de los fármacos , Ofloxacino/efectos adversos , Dolor , Estudios Retrospectivos , Tendinopatía/inducido químicamente
7.
Clin Microbiol Infect ; 12(10): 1030-3, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16961643

RESUMEN

A 3-year retrospective study evaluated the effectiveness and safety of cefepime plus a fluoroquinolone for treating bone and joint infections caused by Gram-negative bacilli (GNB) in 28 patients. Intra-operative cultures yielded primarily Pseudomonas spp. and Enterobacter cloacae. Full recovery (cure) was observed in 79% of patients. There were no serious adverse effects and no resistant organisms were isolated. The results of the study confirmed the safety and effectiveness of cefepime combined with a fluoroquinolone for the treatment of bone and joint infections caused by Gram-negative bacilli.


Asunto(s)
Enfermedades Óseas Infecciosas/tratamiento farmacológico , Cefalosporinas/administración & dosificación , Ciprofloxacina/administración & dosificación , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Artropatías/tratamiento farmacológico , Ofloxacino/administración & dosificación , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Cefepima , Cefalosporinas/uso terapéutico , Ciprofloxacina/uso terapéutico , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Ofloxacino/uso terapéutico , Estudios Retrospectivos
8.
Rev Neurol (Paris) ; 161(10): 979-83, 2005 Oct.
Artículo en Francés | MEDLINE | ID: mdl-16365630

RESUMEN

INTRODUCTION: Meningoencephalitis attributed to Chlamydiae pneumoniae has rarely been reported in the literature. OBSERVATION: We describe the case of a 21-year-old-man admitted for a meningeal syndrome and fever associated with respiratory symptoms and a temporal syndrome. Even though the clinical presentation and certain serological results suggested Chlamydiae infection, some of the biological data raised the possibility of Epstein Barr Virus infection. Intravenous fluoroquinolone therapy led to a successful outcome. CONCLUSION: Meningoencephalitis associated with non neurological symptoms, especially respiratory symptoms, is suggestive of Chlamydia pneumoniae infection. A broad spectrum antibiotic should be prescribed.


Asunto(s)
Infecciones por Chlamydophila , Chlamydophila pneumoniae , Meningoencefalitis/microbiología , Adulto , Infecciones por Chlamydophila/diagnóstico , Humanos , Masculino , Meningoencefalitis/diagnóstico
11.
Rev Med Interne ; 23(3): 273-82, 2002 Mar.
Artículo en Francés | MEDLINE | ID: mdl-11928375

RESUMEN

PURPOSE: Antisynthetase syndrome (AS) is frequently revealed by interstitial lung disease and arthritis. There are mechanic's hand, Raynaud's phenomenon and anti aminoacyl t-RNA synthetase antibodies. The anti JO-1 antibody is the most frequently identified. We report five cases of antisynthetase syndrome with particular clinical features and good response to corticosteroids. METHODS: There are three women and two men with a median age of 59 years at presentation (range: 44-77). Three patients progressively developed AS: the symptoms are dyspnea (three). Raynaud's phenomenon (one), purpura (one) and hyperkeratosis, scaling and fissuring on the lateral sides of the fingers (two). Patients always had skin signs: hyperkeratosis and scaling (five), purpura (one), Raynaud's phenomenon with normal capillaroscopy (two). Lung disease is present in the five cases with interstitial lesions in CT scans (five), trouble of CO diffusion (three/three) and lymphocytic alveolitis (two/two). Moderate muscular disorders are present in five cases (moderate elevated muscular enzyme: five, positive muscle histology: two). Anti-JO-1 antibodies are present in five cases. AS is associated with connective tissue diseases: rheumatoid polyarthritis in one case and Gougerot-Sjögren in three cases. No malignant tumour is associated. Patients have received oral corticosteroid treatment (five/five) with high doses of intravenous perfusions (three/five) with, initially, a good response. For only one patient, immunosuppressive treatment was necessary because of the articular relapse. The interstitial lung disease had a good response to corticosteroids therapy alone in four cases. Because of the relapse during the tapering off of corticosteroids, corticosteroids were increased in one case and immunosuppressive therapy was required in one case. CONCLUSION: The prognosis of AS depends of the interstitial lung disease. High doses of corticosteroids are required. In our study, the response to corticosteroids is good. Immunosuppressive agents must be added in severe and progressive form of interstitial lung disease in AS.


Asunto(s)
Anticuerpos Antinucleares , Autoanticuerpos/análisis , Ligasas/inmunología , Enfermedades Pulmonares Intersticiales/inmunología , Enfermedad de Raynaud/inmunología , Síndrome de Sjögren/inmunología , Corticoesteroides/administración & dosificación , Corticoesteroides/uso terapéutico , Adulto , Anciano , Femenino , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/uso terapéutico , Enfermedades Pulmonares Intersticiales/diagnóstico , Enfermedades Pulmonares Intersticiales/tratamiento farmacológico , Masculino , Radiografía Torácica , Enfermedad de Raynaud/diagnóstico , Síndrome de Sjögren/diagnóstico , Síndrome de Sjögren/tratamiento farmacológico , Síndrome , Factores de Tiempo , Tomografía Computarizada por Rayos X
12.
Rev Med Interne ; 22(6): 582-6, 2001 Jun.
Artículo en Francés | MEDLINE | ID: mdl-11433569

RESUMEN

INTRODUCTION: To better individualize drug hypersensitivity reaction, Bocquet et al. have recently called this adverse drug reaction DRESS (Drug Rash with Eosinophilia and Systemic Symptoms). EXEGESIS: We report two cases of DRESS and highlight the main characteristics of this syndrome. Two patients presented severe febrile skin eruption following drug intake (carbamazepine or sulfazalazine), with hypereosinophilia and hepatitis. All symptoms resolved after drug withdrawal and corticosteroid therapy. DRESS syndrome is an idiosyncratic reaction characterised by febrile eruption, occurring 2 to 6 weeks after the beginning of the treatment, accompanied by systemic symptoms and biological abnormalities (hypereosinophilia, hepatitis). Some complications can occur. This syndrome can be fatal. Numerous drugs can be responsible for this reaction to medication. The physiopathology has not yet been elucidated, and the treatment is not codified, but the triggering agent must immediately be stopped. Corticotherapy is sometimes used. CONCLUSION: It is important to recognize this entity recently named DRESS syndrome because it can mimic other pathologies, is potentially serious, and because withdrawal of the incriminating drug is imperative.


Asunto(s)
Antiinflamatorios no Esteroideos/efectos adversos , Anticonvulsivantes/efectos adversos , Carbamazepina/efectos adversos , Hipersensibilidad a las Drogas/patología , Eosinofilia/inducido químicamente , Exantema/inducido químicamente , Sulfasalazina/efectos adversos , Adolescente , Corticoesteroides/uso terapéutico , Adulto , Enfermedad Hepática Inducida por Sustancias y Drogas , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Pronóstico , Síndrome
13.
Ann Dermatol Venereol ; 126(2): 147-9, 1999 Feb.
Artículo en Francés | MEDLINE | ID: mdl-10352830

RESUMEN

BACKGROUND: There are many causes of macroglossia, including fatty infiltration. Unlike unique or multiple lipomas of the tongue, non-encapsulated adipocyte masses develop in the tongue in symmetrical benign lipomatosis. Only six cases have been reported in the literature. CASE REPORT: A 69-year-old man with a history of chronic alcoholism developed a soft tumefied formation on the lateral margins of the tongue. A yellow-colored content was perceived through the thin mucosa. The formation was bilateral and had developed for more than 10 years. The patient also presented Launois-Bensaude lipomatosis localized on the neck, the nuchal region and the shoulders. DISCUSSION: This is, to our knowledge, the first reported case of symmetrical benign lipomatosis associated with Launois-Bensaude lipomatosis. An analogy between these two conditions has been suggested, but the six earlier cases of lipomatosis of the tongue reported in the literature developed in patients without cutaneous lipomatosis.


Asunto(s)
Lipomatosis , Enfermedades de la Piel , Enfermedades de la Lengua , Anciano , Biopsia , Humanos , Lipomatosis/diagnóstico , Lipomatosis/patología , Masculino , Piel/patología , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/patología , Síndrome , Lengua/patología , Enfermedades de la Lengua/diagnóstico , Enfermedades de la Lengua/patología
14.
Ann Dermatol Venereol ; 126(1): 38-40, 1999 Jan.
Artículo en Francés | MEDLINE | ID: mdl-10095890

RESUMEN

BACKGROUND: Tramadol chlorhydrate (Topalgic) is a powerful analgesic recently introduced in France where its use has spread rapidly. We report a case where this drug induced a maculopapulous toxic skin reaction with secondary erythrodermia. CASE REPORT: A 47-year-old man was treated for lower back pain with tramadol chlorhydrate (50 mg b.i.d.). Otherwise, he was in good general health and was taking no other medications. Shortly after beginning the treatment, he developed a highly pruriginous maculopapulous eruption involving the entire skin surface, hyperthermia and general degradation. There was no skin exfoliation, mucosal involvement nor nodal enlargement. Tramadol was withdrawn and the patient was given corticosteroid therapy. Secondary erythrodermia developed after termination of the corticosteroids. The lesions regressed after tramadol withdrawal. DISCUSSION: Tramadol-induced skin reactions are uncommon and usually benign. In our case, the delay from onset of tramadol and the development of the maculopapulous eruption was very short (four days). The patient was taking no other medication. We hypothesize that the patient had been sensitized by cross-reaction with another compound and recall the fundamental aspects of tramadol and opiate drugs.


Asunto(s)
Analgésicos Opioides/efectos adversos , Erupciones por Medicamentos/diagnóstico , Tramadol/efectos adversos , Analgésicos Opioides/administración & dosificación , Diagnóstico Diferencial , Humanos , Dolor de la Región Lumbar/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Tramadol/administración & dosificación
15.
Reanimation ; 13(3): 226-237, 2004 May.
Artículo en Francés | MEDLINE | ID: mdl-32288722

RESUMEN

Respiratory infections are frequently encountered in the community; these infections are usually associated with only minor consequences. Many different agents, such as influenza and parainfluenza virus, respiratory syncitial virus, rhinovirus, coronavirus, adenovirus and herpes virus can be found in immuno-competent patients. Among these pathogens, cytomegalovirus (CMV) has been found to be responsible for nosocomial pneumonia in ICU. The main problem for viral infections, is the diagnosis, isolation of the pathogen is often difficult and not always reliable and the symptoms not specific. However, influenza is characterised by fever, myalgia, headache and pharyngitis, this infection may be very mild, even asymptomatic, moderate or very severe. Finally, the most recent viral pathogen involved in respiratory disease is a newly discovered coronavirus, the SARS-CoV which was responsible for the worldwide outbreak of Severe Acute Respiratory Syndrome. Viral pneumonia is a common pathology which is probably underdiagnosed in immuno-competent patients; many reports show that even if the diagnosis is difficult to obtain, it is not useless as long as we have, for most of the pathogens, an effective treatment. The gold standard was histology, new techniques like PCR can probably make a difference and should be included in the guidelines to improve diagnostic efficiency.

17.
Med Mal Infect ; 38 Spec No 2: 13-5, 2008 Dec.
Artículo en Francés | MEDLINE | ID: mdl-19185204
18.
J Mycol Med ; 23(1): 57-63, 2013 Mar.
Artículo en Francés | MEDLINE | ID: mdl-23375857

RESUMEN

INTRODUCTION: Cryptococcosis is a serious invasive fungal infection mostly described in patients with cell-mediated immunosuppression. Cryptococcus neoformans osteomyelitis is a rare infection that occurs mainly during disseminated forms. OBSERVATION: A 72-year-old diabetic patient, treated with fludarabine-cyclophosphamide-rituximab (since 10 months) for lymphocytic leukemia presented with osteolysis of the fourth left hand metacarpien the histological examination of which revealed C. neoformans. This bone involvement was associated with costal osteolytis and pulmonary cryptococcosis but central nervous system (CNS) was spared. Fluconazole was administered intravenously for 15 days, then switched to oral route for 6 months with favorable clinical course. This case describes an unusual clinical presentation of disseminated cryptococcosis without CNS involvement with multiple osseous metastases. A review of cryptococcal osteomyelitis cases reported in adult from 2000 to 2011 is also discussed. CONCLUSION: Cryptococcosis is a rare infection that should be discussed in seriously immunocompromized patients presenting with osteomyelitis even in the absence of CNS involvement.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Criptococosis/etiología , Cryptococcus neoformans/aislamiento & purificación , Fungemia/etiología , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Infecciones Oportunistas/microbiología , Osteomielitis/microbiología , Anciano , Anticuerpos Monoclonales de Origen Murino/administración & dosificación , Anticuerpos Monoclonales de Origen Murino/efectos adversos , Antifúngicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Criptococosis/tratamiento farmacológico , Criptococosis/microbiología , Fístula Cutánea/etiología , Fístula Cutánea/microbiología , Ciclofosfamida/administración & dosificación , Ciclofosfamida/efectos adversos , Diabetes Mellitus Tipo 2/complicaciones , Femenino , Fungemia/tratamiento farmacológico , Fungemia/microbiología , Humanos , Huésped Inmunocomprometido , Inmunosupresores/administración & dosificación , Inmunosupresores/efectos adversos , Leucemia Linfocítica Crónica de Células B/complicaciones , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Enfermedades Pulmonares Fúngicas/etiología , Enfermedades Pulmonares Fúngicas/microbiología , Neutropenia/inducido químicamente , Neutropenia/complicaciones , Infecciones Oportunistas/tratamiento farmacológico , Infecciones Oportunistas/etiología , Osteólisis/etiología , Osteomielitis/tratamiento farmacológico , Osteomielitis/etiología , Rituximab , Vidarabina/administración & dosificación , Vidarabina/efectos adversos , Vidarabina/análogos & derivados
19.
Orthop Traumatol Surg Res ; 98(8): 910-4, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23158782

RESUMEN

INTRODUCTION: Joint implant infection rates range between 0.5% and 3%. Contamination may be hematogenous, originating in oro-dental infection and, as in endocarditis, antibiotic prophylaxis has been recommended to cover oro-dental surgery in immunodepressed patients with joint implants less than 2 years old, despite the lack of any formal proof of efficacy. In this context, the cost and side effects of such prophylaxis raise the question of its real utility. MATERIALS AND METHODS: A search of Pubmed was performed using the following keywords: prosthetic joint infection, dental procedure, antibiotic prophylaxis, hematogenous infection, dental infection, bacteremia, and endocarditis. Six hundred and fifty articles were retrieved, 68 of which were analyzed in terms of orthopedic prosthetic infection and/or endocarditis and oro-dental prophylaxis, as relevant to the following questions: frequency and intensity of bacteremia of oro-dental origin, frequency of prosthetic joint infection secondary to dental surgery, and objective efficacy of antibiotic prophylaxis in dental surgery in patients with joint implants. RESULTS: Bacteremia of oro-dental origin is more frequently associated with everyday activities such as mastication than with tooth extraction. Isolated cases of prosthetic contamination from dental infection have been reported, but epidemiological studies in joint implant bearers found that absence of antibiotic prophylaxis during oro-dental surgery did not increase the rate of prosthetic infection. The analysis was not able to answer the question of the efficacy of dental antibiotic prophylaxis in immunodepressed patients; however, oro-dental hygiene and regular dental treatment reduce the risk of prosthetic infection by 30%. DISCUSSION AND CONCLUSION: The present update is in agreement with the conclusions of ANSM expert group, which advised against antibiotic prophylaxis in oro-dental surgery in implant bearers, regardless of implant duration or comorbidity: the associated costs and risks are disproportional to efficacy. LEVEL OF EVIDENCE AND TYPE OF STUDY: Level V; expert opinion.


Asunto(s)
Profilaxis Antibiótica , Prótesis Articulares/efectos adversos , Procedimientos Quirúrgicos Orales , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/prevención & control , Infecciones Relacionadas con Prótesis/etiología , Infecciones Relacionadas con Prótesis/prevención & control , Bacteriemia/etiología , Bacteriemia/prevención & control , Humanos
20.
Med Mal Infect ; 42(3): 102-9, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22341664

RESUMEN

Prosthetic vascular graft infection is a rare but very severe complication with a high death rate. Its optimal management requires appropriate surgical procedures combined with adequate antimicrobial treatment in reference center. The authors wanted to focus on the management of prosthetic vascular graft infection and define the clinical, microbiological, biological, and radiological criteria of vascular graft infection. Complementary investigations, although these are small series, include CT scan, the gold standard for the diagnosis of acute infection with a sensitivity and specificity reaching 100%, but decreased to 55% in case of chronic infection. More recently, PET-scanning was studied and yielded good results in chronic infections (sensitivity 98%, specificity 75.6%, positive predictive value 88.5%, and negative predictive value 84.4%). Managing prosthetic vascular graft infection, as with the orthopedic and vascular infections, requires replacing the vascular prosthesis. There is no correlation between the microbiological data and the location or type of vascular infection. Thus, the postoperative intravenous antibiotherapy should be bactericidal with a broad-spectrum. After obtaining intra-operative microbiological results, de-escalation therapy must include at least one anti-adherence agent, such as rifampicin in staphylococcal infections.


Asunto(s)
Infecciones Bacterianas/diagnóstico , Infecciones Bacterianas/tratamiento farmacológico , Prótesis Vascular/efectos adversos , Diagnóstico por Imagen/métodos , Infecciones Relacionadas con Prótesis/diagnóstico , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Cuidados Posteriores , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Adhesión Bacteriana/efectos de los fármacos , Infecciones Bacterianas/sangre , Infecciones Bacterianas/diagnóstico por imagen , Infecciones Bacterianas/cirugía , Terapia Combinada , Medios de Contraste , Remoción de Dispositivos , Manejo de la Enfermedad , Farmacorresistencia Microbiana , Humanos , Angiografía por Resonancia Magnética , Tomografía de Emisión de Positrones , Valor Predictivo de las Pruebas , Infecciones Relacionadas con Prótesis/sangre , Infecciones Relacionadas con Prótesis/cirugía , Reoperación , Sensibilidad y Especificidad , Tomografía Computarizada por Rayos X , Ultrasonografía Doppler
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA